Meanwhile, ARO-HSD (GSK4532990) siRNA developed by Arrowhead Pharmaceuticals has completed the phase 1 clinical trial (NCT04202354), showing good tolerance with lowered hepatic HSD17B13 expression as well as decreased serum ALT level in NASH patients.353. The gene discussed is HSD17B13; the disease is metabolic dysfunction-associated steatohepatitis.